[HTML][HTML] Chronic lymphocytic leukemia in the SARS-CoV-2 pandemic
AA Arellano-Llamas, J Vela-Ojeda… - Current Oncology …, 2022 - Springer
Abstract Purpose of Review Chronic lymphocytic leukemia (CLL) is the most frequent
lymphoproliferative disease in the elderly of the western world. Immune defective responses …
lymphoproliferative disease in the elderly of the western world. Immune defective responses …
BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review
M Stack, K Sacco, R Castagnoli, AA Livinski… - Clinical …, 2021 - Elsevier
Abstract Introduction The Bruton tyrosine kinase (BTK) regulates B cell and macrophage
signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to …
signaling, development, survival, and activation. Inhibiting BTK has been hypothesized to …
Standard treatment approaches for relapsed/refractory chronic lymphocytic leukemia after frontline chemoimmunotherapy
C Moreno - Hematology 2014, the American Society of …, 2020 - ashpublications.org
Despite the effectiveness of chemoimmunotherapy (CIT), in most cases the clinical course of
chronic lymphocytic leukemia (CLL) is characterized by consecutive episodes of disease …
chronic lymphocytic leukemia (CLL) is characterized by consecutive episodes of disease …
[HTML][HTML] Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia
C Vitale, E Boccellato, L Comba, R Jones, F Perutelli… - Cancers, 2021 - mdpi.com
Simple Summary In chronic lymphocytic leukemia (CLL), immune alterations—affecting both
the innate and adaptive immunity—are very common. As a clinical consequence, patients …
the innate and adaptive immunity—are very common. As a clinical consequence, patients …
[HTML][HTML] Antibody response to the SARS-CoV-2 vaccine and COVID-19 vulnerability during the omicron pandemic in patients with CLL: two-year follow-up of a …
FR Mauro, D Giannarelli, CM Galluzzo, A Visentin… - Cancers, 2023 - mdpi.com
Simple Summary We prospectively analyzed COVID-19 morbidity and severity in 200
consecutive patients with CLL. Increased COVID-19 morbidity was observed in vaccinated …
consecutive patients with CLL. Increased COVID-19 morbidity was observed in vaccinated …
[HTML][HTML] The evolving landscape of chronic lymphocytic leukemia on diagnosis, prognosis and treatment
C Pérez-Carretero, I Gonzalez-Gascon-y-Marin… - Diagnostics, 2021 - mdpi.com
The knowledge of chronic lymphocytic leukemia (CLL) has progressively deepened during
the last forty years. Research activities and clinical studies have been remarkably fruitful in …
the last forty years. Research activities and clinical studies have been remarkably fruitful in …
Relevance of the Bruton tyrosine kinase as a target for COVID-19 therapy
The outbreak of the novel coronavirus disease 2019 (COVID-19) has emerged as one of the
biggest global health threats worldwide. As of October 2020, more than 44 million confirmed …
biggest global health threats worldwide. As of October 2020, more than 44 million confirmed …
The evolving landscape of COVID‐19 and post‐COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on …
A Visentin, T Chatzikonstantinou… - American journal of …, 2023 - Wiley Online Library
In this retrospective international multicenter study, we describe the clinical characteristics
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
and outcomes of patients with chronic lymphocytic leukemia (CLL) and related disorders …
[HTML][HTML] Clinical trials of the BTK inhibitors ibrutinib and acalabrutinib in human diseases beyond B cell malignancies
S Zhu, J Jung, E Victor, J Arceo, S Gokhale… - Frontiers in …, 2021 - frontiersin.org
The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B
cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior …
cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior …
[HTML][HTML] Antibiotic management of patients with hematologic malignancies: from prophylaxis to unusual infections
F Moreno-Sanchez, B Gomez-Gomez - Current Oncology Reports, 2022 - Springer
Abstract Purpose of Review Patients with hematological malignancies are recognized for
their high susceptibility and increased risk of developing infections associated with …
their high susceptibility and increased risk of developing infections associated with …